Invossa Gene Therapy Controversy Grows As Government, Patients Take Action

While the eventual fate of Kolon Life’s gene therapy Invossa is still undecided after interim results from an ongoing probe into its composition, controversy over the product is growing as patients seek compensation from the company and government, and calls grow for a wider investigation.

Cartilage — Korea Confirms Invossa Distributed In Korea Has Different Cell Composition • Source: Shutterstock

South Korea’s drug ministry has confirmed that an active cell component of the version of Kolon Life Science Inc.’s gene therapy Invossa (TG-C) distributed in the country differs to that described in the data submitted at the time of approval, in line with the same test result for the version of the therapy being used in ongoing US clinical trials.

The ministry will now probe further why this has happened before potentially imposing administrative measures on the company, and also...